Tyrosine kinase inhibitors and immunotherapy targeting epidermal growth factor receptor (EGFR) have made significant progress in the treatment of NSCLC3, however, the overall remission and survival rates for patients with NSCLC remain very low, especially in developing countries. Here, EGFR is linked to non-small cell lung carcinoma.